Last reviewed · How we verify
Squamous cell carcinoma of nose
Approved treatments
- Erbitux · Imclone
Erbitux works by binding to the Epidermal Growth Factor Receptor (EGFR) on cancer cells, blocking the receptor's ability to stimulate cell growth and division. - Erbitux · Hellenic Oncology Research Group
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Squamous cell carcinoma of nose patent landscape — cliff calendar, originator estates, attackable patents
- Squamous cell carcinoma of nose treatment landscape brief
- Squamous cell carcinoma of nose treatment updates RSS
Frequently asked questions about Squamous cell carcinoma of nose
What drugs treat Squamous cell carcinoma of nose?
Tracked treatments include Erbitux.
What is the treatment for Squamous cell carcinoma of nose?
Standard treatment for Squamous cell carcinoma of nose includes Erbitux. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Squamous cell carcinoma of nose patent cliff · Squamous cell carcinoma of nose CI report
- Treatment: Erbitux · Imclone
- Treatment: Erbitux · Hellenic Oncology Research Group
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing